Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699499 | Clinical Oncology | 2010 | 7 Pages |
Abstract
The addition of synchronous chemotherapy to accelerated hypofractionated radiotherapy consistently led to grade 3 mucositis. Tumour control rates compare well with published outcomes. Higher mucosal toxicity and lower synchronous chemotherapy compliance compared with other series may suggest that this approach is at the limit of patient tolerability. However, the tumour site investigated and the choice of synchronous chemotherapy agent may also be important. Compliance may be improved using intensity-modulated radiotherapy and agents that do not enhance mucosal toxicity. Longer fractionation will probably increase compliance with chemotherapy, particularly when induction is used before synchronous treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A. Jegannathen, R. Swindell, B. Yap, L. Lee, A. Sykes, K. Mais, P. Sanghera, A. Hartley, J. Glaholm, N. Slevin,